Trial Profile

An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 12 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alirocumab (Primary) ; Atorvastatin; Colestyramine; Ezetimibe; Fenofibrate; Fluvastatin; Lovastatin; Nicotinic acids; Omega-3-fatty-acid; Pravastatin; Rosuvastatin; Simvastatin
Indications Hyperlipoproteinaemia type IIa
Focus Registrational; Therapeutic Use
Sponsors Sanofi

Most Recent Events

01 Dec 2022 Results published in the Arteriosclerosis Thrombosis and Vascular Biology
17 May 2021 Results evaluating efficacy and safety of alirocumab in pediatric patients with Homozygous Familial Hypercholesterolemia presented at the 70th Annual Scientific Session of the American College of Cardiology
06 Aug 2020 This trial has been discontinued in Bulgaria according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com